Abcam, ab32078, Anti-Src (phospho Y529) antibody [Y232]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal SRC phospho Y529 antibody. Suitable for Dot, WB, ICC/IF and reacts with Synthetic peptide, Human, Mouse, Rat samples. Cited in 20 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:Y232,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody will detect Src phosphorylation on Tyrosine 529 of both isoforms. The antibody immunogen shares 93% homology with Fyn and Yes and 85% homology with Fgr. Therefore, it is likely that the antibody will cross-react with these proteins. However, this is just based on BLAST results and no experiments were performed. The sequence numbering is based off the mature form of the protein without the initiator methionine.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Src also known as c-Src is a protein-tyrosine kinase involved in the regulation of many cellular processes. The molecular weight of Src is approximately 60 kDa. Src is ubiquitously expressed in human tissues but shows increased expression in specific tissues like the brain and epithelial cells. This protein has several important roles in cellular signal transduction particularly influencing cell growth differentiation and survival.
Biological function summary
The Src protein interacts with other proteins to modulate cell adhesion motility and angiogenesis forming part of larger protein complexes. Src phosphorylates specific tyrosine residues on its substrates altering their activity interaction or stability. This activity positions Src as an important factor in managing cell communication and structural organization. Src's interaction with focal adhesion complexes emphasizes its functionality in cellular structural integrity and intracellular communication pathways.
Pathways
Src plays a critical role in the integrin and growth factor receptor signaling pathways mediating cross-talk between cell surface receptors and intricate signaling cascades. It closely associates with focal adhesion kinase (FAK) within these pathways influencing cytoskeletal rearrangements and cell movement. Src's function in the epidermal growth factor receptor (EGFR) signaling pathway likewise demonstrates its importance in regulating cellular proliferation and survival mechanisms.
Src has significant implications in oncogenesis particularly in colorectal and breast cancers. Overexpression or abnormal activity of Src associates with tumor progression and metastasis. Within these cancers Src cooperates with various proteins like the EGFR amplifying aberrant cell signaling that contributes to uncontrolled cell growth. Investigating Src's role and regulation could offer insights into novel therapeutic strategies for controlling Src activity in cancer treatment.